TME Pharma Provides Update on Number of Outstanding Shares and Warrants Following First Warrant Y Exercise Period

Regulatory News:

TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), provides an update on the outstanding number of ordinary shares, Warrants Y and Warrants Z following the exercise of 974,365 Warrants Y for €97,436.50 during the completion of the first Warrant Y exercise period.

In this first exercise period, from January 10-16, 2024, five Warrants Y entitled a holder to subscribe for two ABSA Z, each costing €0.25 and comprised of one ALTME share and one Warrant Z (Bon de souscription d’actions Z).

As a result of these exercises, 389,746 new ordinary shares and 389,746 Warrants Z were issued by TME Pharma and settled today. The following numbers of TME Pharma securities are thus issued and outstanding:

• ALTME ordinary shares (ISIN: NL0015000YE1): 17,710,591
• Warrants Y (ISIN : NL0015001SS1): 9,851,163
• Warrants Z (ISIN: NL0015001SR3): 389,746.

The second and final exercise period for the Warrants Y will run from February 12-16, 2024. Warrants Y that have not been exercised by the end of the exercise period at the latest will become null and void.

The first Warrant Z exercise period will run from February 26 to March 22, 2024, with settlement on March 29, 2024. Warrants Z may be exercised through June 2025.

Additional Information

The characteristics, terms and conditions and dilution resulting from the transaction are summarized in the press releases published on November 24 and November 28, 2023 and in the dedicated Rights Issue page on the TME Pharma website.

Dilution

The table below summarizes the dilution from the new ordinary shares issued today, and the maximum additional dilutive potential for an investor who did NOT participate in the transaction should all remaining Warrants Y and all potential Warrants Z be exercised. Shareholders who participated fully in the transaction, i.e. who purchased the ABSA Y and subsequently exercise both Warrants Y and Z will not be diluted by this transaction.

Description	Shares to be issued	Total shares outstanding	Dilution (cumulative)	Shareholder starting with 1% on January 22, 2024, would then hold
Outstanding shares on January 22, 2024